1. Home
  2. AMST vs MBIO Comparison

AMST vs MBIO Comparison

Compare AMST & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

N/A

Current Price

$0.96

Market Cap

6.9M

Sector

Technology

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.47

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMST
MBIO
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
4.1M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
AMST
MBIO
Price
$0.96
$0.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 86.3K
25.8K
Earning Date
09-23-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
38.83
★ 98.99
EPS
N/A
★ N/A
Revenue
★ $364,777.00
N/A
Revenue This Year
$19,089.81
N/A
Revenue Next Year
$22.86
$405.45
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 230.24
N/A
52 Week Low
$0.77
$0.47
52 Week High
$3.90
$1.84

Technical Indicators

Market Signals
Indicator
AMST
MBIO
Relative Strength Index (RSI) 43.27 34.45
Support Level $0.99 $0.47
Resistance Level $1.10 $0.56
Average True Range (ATR) 0.06 0.03
MACD -0.01 -0.00
Stochastic Oscillator 13.33 10.21

Price Performance

Historical Comparison
AMST
MBIO

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: